Prevalence of Amyloid-Related Imaging Abnormalities in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Findings from Ongoing Clinical Trials of Oral Anti-Amyloid Agent ALZ-801 (Valiltramiprosate) (P5-6.003)Susan Abushakra, Martin Tolar, Joyce Suhy et al.|Neurology|2023Cited by 3
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, Martin Tolar, P. Murali Doraiswamy et al.|CNS Drugs|2025Cited by 2
Prevalence of Cerebral Microhemorrhages and Cortical Superficial Siderosis in APOE4/4 Homozygotes with Early Alzheimer’s disease: Baseline Findings from Phase 3 Trial of Oral ALZ‐801 in APOE4/4 Homozygotes (APOLLOE4)Susan Abushakra, Martin Tolar, Rosalind McLaine et al.|Alzheimer s & Dementia|2023Cited by 0
Low Incidence of Amyloid Related Imaging Abnormalities over 104 Weeks in a Phase 2 Study of Amyloid Anti‐Oligomer Agent ALZ‐801: Phase 2 Study Results in Biomarker Positive APOE4 Carriers with Early Alzheimer’s Disease (AD)Patrick Kesslak, Martin Tolar, Susan Abushakra et al.|Alzheimer s & Dementia|2024Cited by 0
Safety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early ADPatrick Kesslak, Martin Tolar, Susan Abushakra et al.|Alzheimer s & Dementia|2025Cited by 0